KR20080066095A - 양성 호르몬 의존성 부인과 질병의 치료 및 예방을 위한메조프로게스틴 (프로게스테론 수용체 조절물질) - Google Patents

양성 호르몬 의존성 부인과 질병의 치료 및 예방을 위한메조프로게스틴 (프로게스테론 수용체 조절물질) Download PDF

Info

Publication number
KR20080066095A
KR20080066095A KR1020087016247A KR20087016247A KR20080066095A KR 20080066095 A KR20080066095 A KR 20080066095A KR 1020087016247 A KR1020087016247 A KR 1020087016247A KR 20087016247 A KR20087016247 A KR 20087016247A KR 20080066095 A KR20080066095 A KR 20080066095A
Authority
KR
South Korea
Prior art keywords
mesoprogestin
treatment
prevention
bleeding
endometriosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020087016247A
Other languages
English (en)
Korean (ko)
Inventor
크리스토프 슈발리스츠
발터 엘거
게르트 슈베르트
Original Assignee
바이엘 쉐링 파마 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 쉐링 파마 악티엔게젤샤프트 filed Critical 바이엘 쉐링 파마 악티엔게젤샤프트
Publication of KR20080066095A publication Critical patent/KR20080066095A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020087016247A 1999-08-31 2000-08-31 양성 호르몬 의존성 부인과 질병의 치료 및 예방을 위한메조프로게스틴 (프로게스테론 수용체 조절물질) Withdrawn KR20080066095A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38614199A 1999-08-31 1999-08-31
US09/386,141 1999-08-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077011455A Division KR100864547B1 (ko) 1999-08-31 2000-08-31 양성 호르몬 의존성 부인과 질병의 치료 및 예방을 위한메조프로게스틴 (프로게스테론 수용체 조절물질)

Publications (1)

Publication Number Publication Date
KR20080066095A true KR20080066095A (ko) 2008-07-15

Family

ID=23524338

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020087016247A Withdrawn KR20080066095A (ko) 1999-08-31 2000-08-31 양성 호르몬 의존성 부인과 질병의 치료 및 예방을 위한메조프로게스틴 (프로게스테론 수용체 조절물질)
KR1020027002790A Expired - Fee Related KR100755109B1 (ko) 1999-08-31 2000-08-31 양성 호르몬 의존성 부인과 질병의 치료 및 예방을 위한메조프로게스틴 (프로게스테론 수용체 조절물질)
KR1020077011455A Expired - Fee Related KR100864547B1 (ko) 1999-08-31 2000-08-31 양성 호르몬 의존성 부인과 질병의 치료 및 예방을 위한메조프로게스틴 (프로게스테론 수용체 조절물질)

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020027002790A Expired - Fee Related KR100755109B1 (ko) 1999-08-31 2000-08-31 양성 호르몬 의존성 부인과 질병의 치료 및 예방을 위한메조프로게스틴 (프로게스테론 수용체 조절물질)
KR1020077011455A Expired - Fee Related KR100864547B1 (ko) 1999-08-31 2000-08-31 양성 호르몬 의존성 부인과 질병의 치료 및 예방을 위한메조프로게스틴 (프로게스테론 수용체 조절물질)

Country Status (34)

Country Link
EP (1) EP1229906B1 (https=)
JP (1) JP2003535029A (https=)
KR (3) KR20080066095A (https=)
AR (1) AR025457A1 (https=)
AT (1) ATE375160T1 (https=)
AU (1) AU781840B2 (https=)
BG (1) BG65817B1 (https=)
BR (1) BR0014161A (https=)
CA (1) CA2382580C (https=)
CO (1) CO5200772A1 (https=)
CZ (1) CZ2002704A3 (https=)
DE (1) DE60036723T2 (https=)
DK (1) DK1229906T3 (https=)
EA (1) EA007854B1 (https=)
EE (1) EE05172B1 (https=)
ES (1) ES2295050T3 (https=)
HR (1) HRP20020267A2 (https=)
HU (1) HUP0202429A3 (https=)
IL (1) IL148416A0 (https=)
LT (1) LT5034B (https=)
LV (1) LV12941B (https=)
ME (1) MEP13808A (https=)
MX (1) MXPA02002191A (https=)
NO (1) NO20020999L (https=)
NZ (1) NZ517471A (https=)
PE (1) PE20010578A1 (https=)
PL (1) PL198790B1 (https=)
PT (1) PT1229906E (https=)
RO (1) RO122179B1 (https=)
RS (1) RS50283B (https=)
SI (1) SI20852B (https=)
SK (1) SK287192B6 (https=)
UA (1) UA78184C2 (https=)
WO (1) WO2001015679A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003255355A1 (en) * 2002-08-02 2004-02-25 Schering Aktiengesellschaft Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
RU2301691C1 (ru) * 2005-12-20 2007-06-27 Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Российской академии медицинских наук Способ восстановительного лечения женщин репродуктивного возраста с тазовыми перитонеальными спайками с фиксированной или субфиксированной ретродевиацией матки
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
RU2339392C1 (ru) * 2007-05-21 2008-11-27 Федеральное Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Росмедтехнологий Способ остановки маточных кровотечений в пубертатном периоде
JP4709328B2 (ja) * 2009-06-17 2011-06-22 国立大学法人 熊本大学 月経困難症の予防及び／又は治療薬
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
JP2022548314A (ja) * 2019-09-23 2022-11-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 妊娠を遷延させるためおよび月経または妊娠の合併症の処置の方法
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633244A1 (de) 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
US5696127A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
EP1043325B1 (en) * 1994-12-22 2004-06-16 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
UA37259C2 (uk) 1995-02-02 2001-05-15 Шерінг Актієнгезеллшафт Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
WO1997041145A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
EP1144396A2 (en) * 1999-01-14 2001-10-17 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
HK1043788A1 (zh) * 1999-05-04 2002-09-27 American Home Products Corporation 四環黃體酮受體調節劑化合物及方法

Also Published As

Publication number Publication date
ATE375160T1 (de) 2007-10-15
PL353930A1 (en) 2003-12-15
CA2382580C (en) 2009-05-19
PT1229906E (pt) 2008-01-18
RS50283B (sr) 2009-09-08
KR20070058023A (ko) 2007-06-07
HUP0202429A3 (en) 2004-04-28
LT5034B (lt) 2003-07-25
WO2001015679A3 (en) 2001-11-22
EE05172B1 (et) 2009-06-15
UA78184C2 (en) 2007-03-15
MEP13808A (en) 2010-06-10
JP2003535029A (ja) 2003-11-25
SI20852A (sl) 2002-10-31
DE60036723D1 (de) 2007-11-22
EE200200104A (et) 2003-04-15
AU781840B2 (en) 2005-06-16
KR20020027616A (ko) 2002-04-13
ES2295050T3 (es) 2008-04-16
KR100864547B1 (ko) 2008-10-20
NZ517471A (en) 2004-02-27
DK1229906T3 (da) 2008-02-11
EA200200282A1 (ru) 2002-10-31
WO2001015679A2 (en) 2001-03-08
CZ2002704A3 (cs) 2003-02-12
AU6946600A (en) 2001-03-26
PE20010578A1 (es) 2001-06-04
CA2382580A1 (en) 2001-03-08
CO5200772A1 (es) 2002-09-27
NO20020999L (no) 2002-03-14
YU14002A (sh) 2006-01-16
DE60036723T2 (de) 2008-07-17
BG65817B1 (bg) 2010-01-29
SK287192B6 (sk) 2010-02-08
HUP0202429A2 (en) 2002-10-28
BR0014161A (pt) 2002-05-21
EA007854B1 (ru) 2007-02-27
KR100755109B1 (ko) 2007-09-04
EP1229906A2 (en) 2002-08-14
AR025457A1 (es) 2002-11-27
NO20020999D0 (no) 2002-02-28
BG106442A (bg) 2002-09-30
MXPA02002191A (es) 2002-09-30
EP1229906B1 (en) 2007-10-10
RO122179B1 (ro) 2009-02-27
PL198790B1 (pl) 2008-07-31
SK2992002A3 (en) 2002-07-02
LT2002031A (en) 2003-02-25
SI20852B (sl) 2009-06-30
IL148416A0 (en) 2002-09-12
HRP20020267A2 (en) 2004-04-30
LV12941B (en) 2003-06-20

Similar Documents

Publication Publication Date Title
Vannuccini et al. Role of medical therapy in the management of uterine adenomyosis
US20120015917A1 (en) Use of Estrogenic Compounds in Combination with Progestogenic Compounds in Hormone-Replacement Therapy
KR100864547B1 (ko) 양성 호르몬 의존성 부인과 질병의 치료 및 예방을 위한메조프로게스틴 (프로게스테론 수용체 조절물질)
US20110033519A1 (en) Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use
US8193252B1 (en) Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
KR100729311B1 (ko) 호르몬 대체 요법(ｈｒｔ)용 조성물의 성분으로서의메조프로게스틴 (프로게스테론 수용체 조절물질)
Ashok et al. The antiprogestogen mifepristone: a review
CN1450892A (zh) 中孕酮(孕酮受体调节剂)用于治疗和预防激素依赖性良性妇科疾病
HK1062391A (en) Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
Joshi et al. Medical management of endometriosis
US7629334B1 (en) Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
Kulp et al. Endometriosis: Pathogenesis and management of pain
Patel 6 Hysteroscopic Implications

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20080703

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid